Smith & Nephew plc (LON:SN - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,026.34 ($13.52) and traded as high as GBX 1,076.50 ($14.18). Smith & Nephew shares last traded at GBX 1,067.50 ($14.06), with a volume of 1,953,695 shares trading hands.
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. reiterated an "overweight" rating and set a GBX 1,180 ($15.55) target price on shares of Smith & Nephew in a report on Tuesday, January 14th.
Check Out Our Latest Report on SN
Smith & Nephew Trading Up 1.1%
The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The stock has a market capitalization of £11.85 billion, a PE ratio of 38.90, a P/E/G ratio of 0.46 and a beta of 0.62. The stock has a 50 day moving average price of GBX 1,050.30 and a 200-day moving average price of GBX 1,023.68.
Smith & Nephew Increases Dividend
The business also recently announced a dividend, which will be paid on Wednesday, May 28th. Investors of record on Thursday, March 27th will be given a dividend of $0.23 per share. The ex-dividend date is Thursday, March 27th. This is an increase from Smith & Nephew's previous dividend of $0.14. This represents a yield of 1.61%. Smith & Nephew's payout ratio is 104.41%.
Insiders Place Their Bets
In related news, insider Sybella Stanley purchased 3,810 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of GBX 1,101 ($14.51) per share, for a total transaction of £41,948.10 ($55,267.59). Also, insider Jeremy (Jez) Maiden acquired 1,855 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were purchased at an average cost of GBX 1,070 ($14.10) per share, for a total transaction of £19,848.50 ($26,150.86). Company insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
